-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: BIO Investor Forum
Team at BrainCells using brain cells
An interview with James A. Schoeneck, Chief Executive Officer, BrainCells, Inc.: Can you describe the top priorities or upcoming milestones for your company? BrainCells Inc. has two up-coming milestones in 1Q10: the advancement of BCI-632 into a Phase 1 clinical trial, and Phase 2 data for BCI-540 in patients with treatment resistant depression and anxiety. Both compounds have novel mechanisms of action. In July, the company announced the outcome of an exploratory Phase 2 study Read More >
Anadys Pharmaceuticals Begins Phase II Study Dosing of ANA598
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). The study will evaluate ANA598 over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, in treatment naïve HCV patients. ANA598 is an investigational, oral, nonnucleoside polymerase inhibitor. Anadys has completed three Phase I clinical studies of ANA598 that have demonstrated potent antiviral activity and good tolerability. Read More >
XOMA Collaboration with Arana Therapeutics
XOMA Ltd. (Nasdaq:XOMA) and Arana Therapeutics Limited, a wholly-owned subsidiary of Cephalon, Inc. (Nasdaq:CEPH) will collaborate on multiple proprietary XOMA antibody R&D technologies, including a new antibody phage display library, and a suite of integrated information and data management systems. Arana will pay XOMA a fee of $6 million and XOMA will receive milestone payments and royalties on product sales. The proprietary antibody library covered by the collaboration is one of a series of proprietary Read More >
PTC Therapeutics Announces Phase III Trial of Ataluren
PTC Therapeutics, Inc. (PTC) initiated a Phase III trial of ataluren, an investigational protein restoration therapy for patients with nonsense mutation cystic fibrosis (nmCF). Ataluren is the first investigational drug designed to address the underlying cause of nonsense mutation cystic fibrosis. The primary objective of the registration-directed double-blind, placebo-controlled study is to evaluate whether ataluren can improve lung function, as measured by forced expiratory volume in one second (FEV1), in patients with nmCF. An orally Read More >
The latest from Trubion Pharmaceuticals
An interview with Dr. Peter A. Thompson, MD, FACP, President, CEO, & Chairman of the Board of Directors of Trubion Pharmaceuticals: What is one aspect of your company that you feel would be most attractive or exciting to investors? We currently have three product candidates in the clinic with two, strategic collaborations underlying their development – Wyeth for our CD20 programs and Facet for our CD37 programs. Data disclosures later this year from key clinical trials Read More >
